Oncopeptides AB (ONCO) - Total Liabilities

Latest as of December 2025: Skr193.73 Million SEK ≈ $20.85 Million USD

Based on the latest financial reports, Oncopeptides AB (ONCO) has total liabilities worth Skr193.73 Million SEK (≈ $20.85 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Oncopeptides AB (ONCO) long-term investment share to see how much of total assets are deployed in long-term investments.

Oncopeptides AB - Total Liabilities Trend (2014–2025)

This chart illustrates how Oncopeptides AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Oncopeptides AB (ONCO) total assets.

Oncopeptides AB Competitors by Total Liabilities

The table below lists competitors of Oncopeptides AB ranked by their total liabilities.

Company	Country	Total Liabilities
RoyalTek Co Ltd TWO:3306	Taiwan	NT$470.54 Million
NWF GROUP PLC LS-25 F:NYY	Germany	€182.60 Million
Dardanel Onentas Gida Sanayi AS IS:DARDL	Turkey	TL446.32 Million
Pembangunan Perumahan PT JK:PTPP	Indonesia	Rp40.22 Trillion
Kilitch Drugs (India) Limited NSE:KILITCH	India	Rs1.34 Billion
Autopistas del Sol BA:AUSO	Argentina	AR$249.27 Billion
LUOYANG GLASS CO. H YC 1 F:LUG	Germany	€10.15 Billion
Thanapiriya Public Company Limited BK:TNP	Thailand	฿362.68 Million

Liability Composition Analysis (2014–2025)

This chart breaks down Oncopeptides AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ONCO equity financing ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.63	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-3.29	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	1.44	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Oncopeptides AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Oncopeptides AB (2014–2025)

The table below shows the annual total liabilities of Oncopeptides AB from 2014 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr193.73 Million ≈ $20.85 Million	+2.01%
2024-12-31	Skr189.91 Million ≈ $20.44 Million	+4.58%
2023-12-31	Skr181.60 Million ≈ $19.54 Million	+99.49%
2022-12-31	Skr91.03 Million ≈ $9.80 Million	-60.16%
2021-12-31	Skr228.51 Million ≈ $24.59 Million	-38.22%
2020-12-31	Skr369.86 Million ≈ $39.80 Million	+88.25%
2019-12-31	Skr196.47 Million ≈ $21.14 Million	+52.66%
2018-12-31	Skr128.70 Million ≈ $13.85 Million	+108.19%
2017-12-31	Skr61.82 Million ≈ $6.65 Million	+111.01%
2016-12-31	Skr29.30 Million ≈ $3.15 Million	+318.39%
2015-12-31	Skr7.00 Million ≈ $753.53K	+26.91%
2014-12-31	Skr5.52 Million ≈ $593.73K	--

About Oncopeptides AB

ST:ONCO Sweden Biotechnology

Market Cap

$71.37 Million

Skr663.20 Million SEK

Market Cap Rank

#20613 Global

#366 in Sweden

Share Price

Skr1.74

Change (1 day)

+4.19%

52-Week Range

Skr1.27 - Skr6.16

All Time High

Skr343.59